The Pharmacology of the Hypouricemic Effect of Benzbromarone
The pharmacological reduction of the serum uric acid in man has been commonly achieved by the use of compounds which increase the renal excretion of uric acid. Although numerous uricosuric drugs have been available, sulfinpyrazone and probenecid have gained the widest usage. Recently a new class of uricosuric compounds, the benzofurans, has been discovered and tested. One of these compounds, benzbromarone, has been found useful in the clinical management of hyperuricemia (for bibliography see 1). In addition to its uricosuric properties it has been proposed that the hypouricemic effects of benzbromarone may also result from the inhibition of uric acid synthesis. We have evaluated the mechanism by which benzbromarone could lower the serum uric acid in man (1).
KeywordsUric Acid Salicylic Acid Xanthine Oxidase Serum Uric Acid Acetylsalicylic Acid
Unable to display preview. Download preview PDF.
- 1.Sinclair, D.S. and Fox, I.H. 1975. The Pharmacology of hypouricemic effect of benzbromarone. J. Rheumat. 2: 437–445.Google Scholar
- 2.Begemann, H. and I. Neu. 1975. Die behandlung der urikopathie met benzbromaronum unter besonderer berucksichtigung der neireninsuffizienz. Therapiewoche 25:2184–2194.Google Scholar
- 3.Muller, M.M., Fuchs, H., Pischek, G. and Bresnik, W. 1975. Purinstoffwechsel und harnsaurepool bei gichtpatienten unter benzbromaronthérapie. Therapiewoche 25:514–521.Google Scholar